copper dotatate CU-64: Clinical Trials

8 trials of copper dotatate CU-64, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 2 Phase 1, 2 Phase 2, 1 Not applicable, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 1, Terminated 1
Phase 22Active not recruiting 1, Unknown 1
Not applicable1Completed 1
Phase 31Recruiting 1

Follow copper dotatate CU-64: new trials by email Literature Review of copper dotatate CU-64 trials Research Report on copper dotatate CU-64

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Stereotactic Body Radiation Therapy, Lutetium Lu 177 Dotatate, Computed Tomography - Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm
Phase 1RecruitingEmory University152025-10-142026-03-02
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 16 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., 177Lu-Dotatate (7.4 Gigabecquerel/cycle) during 30 min intravenous infusion every 8 weeks (q8w) x 4 cycles; 2) and 3) as in the experimental arm., Amino acid solution - Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
Phase 3RecruitingGrupo Espanol de Tumores Neuroendocrinos1662025-06-122026-09-16
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
[68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB - Metastatic Neuroendocrine Prostate Cancer
Phase 1TerminatedNovartis Pharmaceuticals312024-07-292026-11-17
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
18F-FDG, 64Cu-Dotatate - GEP-NET, Neuroendocrine Tumors
Phase 2UnknownCopenhagen University Hospital, Rigshospitalet2002023-01-172023-11-22
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Phase 2Active not recruitingAdvanced Accelerator Applications112022-08-312026-02-12
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Lutetium [177Lu] oxodotreotide/dotatate - Neuroendocrine Tumors, Intestinal Neoplasms
RecruitingSociedad EspaƱola de Medicina Nuclear e Imagen Molecular50002021-05-102022-12-23
Somatostatin Receptor Imaging in Cardiac Sarcoidosis
Cu-64 DOTATATE - Cardiac Sarcoidosis
WithdrawnCopenhagen University Hospital, Rigshospitalet2016-06-012020-10-14
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
[177Lu] DOTA-TATE - Neuroendocrine Tumors
Not applicableCompletedInstituto Nacional de Cancerologia, Columbia392013-11-012019-11-14

Conditions studied

Gastro-enteropancreatic neuroendocrine tumor (4)  ·  Neuroendocrine Tumors (4)  ·  Carcinoma, Neuroendocrine (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Gastrointestinal Neoplasms (1)  ·  Intestinal Diseases (1)  ·  Intestinal Neoplasms (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Germ Cell and Embryonal (1)

Sponsors

Copenhagen University Hospital, Rigshospitalet (2)  ·  Advanced Accelerator Applications (1)  ·  Emory University (1)  ·  Grupo Espanol de Tumores Neuroendocrinos (1)  ·  Instituto Nacional de Cancerologia, Columbia (1)  ·  Novartis Pharmaceuticals (1)  ·  Sociedad EspaƱola de Medicina Nuclear e Imagen Molecular (1)

Countries

Spain (4)  ·  France (3)  ·  United States (3)  ·  Denmark (2)  ·  United Kingdom (2)  ·  Colombia (1)  ·  Germany (1)  ·  Poland (1)

Top investigators

Andreas Kjaer, MD (1)  ·  Eric Baudin Baudin, M.D., Ph.D. (1)  ·  Mercedes Dr Mitjavila Casanovas, MD-PhD (1)  ·  Pretesh Patel, MD (1)  ·  Rasmus S Ripa, MD, DMSc (1)

Results publications

PMID 36877234, PMID 40198358

NIH funding

2023 (1), P30CA138292 (1)